Skip to content
Screener

Novavax NVAX Nuvaxovid sales — Total Revenue

Other product segments

Licensing, royalties, and other
$37.84M-83.4%
Cost reimbursements
$22.6M+249%
Upfront fee amortization
$8.73M-28.9%
Milestones amortization
$3.76M-33.6%
Royalties
$700K-86.0%
Support services
$265K-4.7%
Milestones
$0-100%
Upfront fee
$0-100%

Similar metrics at other companies

RB Global logo
RBAInventory sales revenue — Total Revenue
$336.9M+31.6%
Custom Truck One Source logo
CTOSEquipment Sales — Total Revenue
$292.63M+6.9%
Moderna logo
MRNANet product sales — Total Revenue
$352M+309%
EVgo, Inc. logo
EVGORegulatory credit sales — Total Revenue
$4.69M+91.4%
CorMedix logo
CRMDProduct sales, net — Total Revenue
$121.92M+212%
Custom Truck One Source logo
CTOSParts sales and services — Total Revenue
$31.77M-1.0%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%—
Debt / equity1.5×—
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product sales
Nuvaxovid™ sales(1)—$(2,093)$9,558$605,931
Supply sales(2)18,85412,81751,49626,471
Total Product sales$18,854$10,724$61,054$632,402

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's nuvaxovid sales — total revenue?
Novavax (NVAX) reported nuvaxovid sales — total revenue of $0 in Q2 2026.
How has Novavax's nuvaxovid sales — total revenue changed year-over-year?
Novavax's nuvaxovid sales — total revenue increased by 100.0% year-over-year, from -$2.09M to $0.
What is the long-term trend for Novavax's nuvaxovid sales — total revenue?
Over 2 years (2023 to 2025), Novavax's nuvaxovid sales — total revenue has grown at a 8.5% compound annual growth rate (CAGR), from $531.39M to $625.18M.
What does nuvaxovid sales — total revenue mean?
This metric represents the total gross revenue generated from the commercial sale and distribution of the company's primary vaccine product. It serves as a key indicator of market adoption, product demand, and the effectiveness of the company's commercialization strategy within the infectious disease vaccine market. Tracking this figure allows investors to assess the revenue contribution of the core product line relative to the company's overall financial performance.

Ask your AI about Novavax's nuvaxovid sales — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude